ClinicalTrials.gg
RecruitingNCT06877715CASSPERUpdated May 8, 2025

Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome

An observational study in Prader-Willi Syndrome, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by University Hospital, Toulouse · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
75
Ages
3 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse — 6 open to participants now, 6 under way, 1 of them phase 3. Prader-Willi Syndrome · University Hospital, Toulouse.

Started
2025
with 1 other
Observational
3 of 17
3 open now
Registered
16th of 17
by date

Among the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, this one is one of 2 that started in 2025, is one of 3 observational ones, and was the 16th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

6 of the 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 3 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Prader-Willi Syndrome by University Hospital, Toulouse, or all of them as a file.
02

Study summary

Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction. Individuals with PWS often exhibit social interaction challenges, intellectual deficits, significant eating disorders, mood disturbances, and sensory-related autistic features. Although PWS is recognized by DSM-5 as a genetic cause of Autism Spectrum Disorder (ASD), ASD diagnosis in PWS remains rare in France. The CASSPER study aims to investigate the distinct autistic and sensory profiles in children with PWS, also analyzing the potential impact of early oxytocin treatment on these manifestations, in line with recommendations for early and tailored intervention.

Read the detailed description

Prader-Willi syndrome (PWS) is a rare and complex neurodevelopmental disorder (NDD) with genetic origin linked to chromosomal damage in the 15q11-q13 region and characterised by hypothalamic dysfunction. At the psychiatric level, patients with PWS display difficulties in social interaction, mild to moderate intellectual deficit, major eating disorders, mood disorders and autistic manifestations, including hypo-/hyper-reactivity to sensory stimuli.

While the International Classification (DSM-5) lists PWS as one of the genetic causes of Autism Spectrum Disorder (ASD), little is known about the interaction between autistic traits, sensory features and PWS.

To date, assessment and diagnosis of ASD in PWS remains exceptional in standard care in France, despite the obvious importance of correct assessment for early identification and intervention.

In this context, the CASSPER study aims to identify the specificity of PWS in terms of autistic symptomatology and sensory characteristics. The CASSPER study is in line with the recommendations of the French National Health Authority (HAS) for early and appropriate guidance of children with PWS.

In addition, almost all children with PWS under the age of 5 have received early treatment with oxytocin (OT). As the neuromodulatory effect of OT treatment and the involvement of this neurohormone in the development of attachment, social interaction and sensory processing may explain a difference in autistic symptomatology, this parameter will be included in the analyses.

The CASSPER study aims to fill gaps in our knowledge of PWS and its care and could be useful more generally to improve our understanding of autistic manifestations in NDD of genetic origin.

03

Conditions studied

  • Prader-Willi Syndrome

Keywords

  • Prader-Willi syndrome
  • Autism Spectrum Disorder
  • Autistic Symptomatology
  • Sensory profile
04

Who can participate

Ages eligible
3 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of children aged 3 to 16 years who have been diagnosed with Prader-Willi syndrome through genetic confirmation, recruited from several hospital centers in France.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Child with genetically confirmed PWS and identification of genetic subtype;
  • Child aged between 3 and 16 years;
  • Hospitalisation or multidisciplinary consultation planned for the child's routine follow-up at one of the investigating centres;
  • No parental/legal guardian objection.

Exclusion criteria

Exclusion Criteria:

  • Change in psychotropic treatment (start, change in dose or discontinuation) in the past 3 months;
  • Inability to provide clear information to parents/legal guardian;
  • Not covered by social security.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • Children Aged 3 to 16 Years

    Other: psychological and sensorial tests

Interventions

  • Otherpsychological and sensorial tests

    children receive questionnaires and sensorial test

06

What researchers measure

Primary outcomes

  1. Composite criteria : Autistic Symptomatology in Children with Prader-Willi Syndrome: Prevalence, Symptom Specificity, and Variability by Age and Genetic Subtype

    The tests used are the ADOS-2 and ADI-R tests. The ADOS-2 test is used for evaluating the ASD symptoms. It consists of structured and semi-structured activities designed to assess communication, social interaction, play, and restricted or repetitive behaviors. The best possible score is 0, while the worst possible score is 10. The other test is ADI-R. The ADI-R is a structured interview used to assess behaviors and developmental history related to ASD. The responses are scored to evaluate the presence and severity of ASD symptoms, helping to support the diagnosis.

    Time frame: day 1 to day 3

Secondary outcomes

  1. Composite criteria : Characterization of the sensory profile of children with PWS

    The PIPS is a program designed to assess and support sensory processing differences in individuals, particularly those with autism. It helps identify sensory sensitivities and adapt interventions accordingly. The highest score is 140, and each modality has a maximum score of 20. The ESA-EA is a sensory assessment tool specifically for individuals with autism. The U-Sniff measures olfactory function by testing an individual's ability to identify specific odors.

    Time frame: day 1 to day 3

  2. Composite criteria : Correlation Between Autistic Symptoms, Sensory Profile, and Cognitive-Behavioral Disorders, Including Eating Disorders

    This study examines the correlation between autism disorder/sensory profile assessments (ADOS-2, ADI-R, PIPS, ESA-EA, U-Sniff test) and behavioral/cognitive assessments (Vineland-II, CBCL, Dykens questionnaire, IQ). The Vineland-II is a semi-structured interview assessing autonomy and adaptive skills. The CBCL evaluates behavioral problems and social skills using a Likert scale, with T-scores indicating severity across clinical subscales. The hyperphagia tool for Prader-Willi Syndrome uses a 5-point Likert scale to rate behaviors, calculating total scores and subscores for Hyperphagic Behavior, Drive, and Severity, along with a specific HQ-CT score for clinical trials. Higher scores indicate more severe symptoms in each tool.

    Time frame: day 1 to day 3

  3. Composite criteria : Assessing the Impact of Autistic Symptomatology and Sensory Profile on Family Burden and Quality of Life

    ZBI measures parents' perception of the burden associated with their child's disability, using a 5-point Likert scale ("0" = never, "4" = almost always). A total score is calculated by summing the 22 items, with higher scores indicating a greater burden. IOFS explores the impact of a child's disability on the family's quality of life. Parents rate statements on a 4-point Likert scale ("strongly agree" = 1, "strongly disagree" = 4), and a total score is calculated after reversing scores. Higher scores reflect a greater impact on family quality of life.

    Time frame: day 1 to day 3

  4. Composite criteria : comparison of Autistic Symptomatology, Sensory Profile, and Developmental Profile in 5-7 Year-Old Children: Early OT Treatment vs. Untreated

    "In the 5-7 year age group, comparison of scores and subscores between the early OT-treated children group and the untreated children group regarding: The specificity of autistic symptomatology (ADOS-2, ADI-R) Sensory profile (PIPS, ESA-EA, U-sniff test) Behavioral and cognitive profile (Vineland-II, CBCL, Dykens questionnaire, IQ) The impact of the condition (ZBI, IOFS)

    Time frame: day 1 to day 3

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Oct 2026, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Apr 7, 2025
Primary completionEst.
Oct 30, 2026
CompletionEst.
Oct 30, 2026
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06877715
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Apr 7, 2025
Primary completion
Oct 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
May 8, 2025

Study contacts

Nadege ALGANS
Contact
algans.n@chu-toulouse.fr
0561777204 ext. +33
Sophie Cabal
principal investigator · University Hospital of Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion